Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension

S. Suzuki; T. Hashimoto; S. Kusano; Kakota Gaston Kapuku; T. Utsunomiya; K. Yano

Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension

S. Suzuki, T. Hashimoto, S. Kusano, Kakota Gaston Kapuku, T. Utsunomiya, K. Yano

GPI

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.

Original language	English (US)
Pages (from-to)	1152-1156
Number of pages	5
Journal	Arzneimittel-Forschung/Drug Research
Volume	43
Issue number	11
State	Published - Jan 1 1993

Keywords

(±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate
CAS 86780-90-7
MPC-1304
antihypertensives
hypertension, essential

ASJC Scopus subject areas

Drug Discovery

Access to Document

Fingerprint Dive into the research topics of 'Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension'. Together they form a unique fingerprint.

Cite this

@article{128a87e4f6524e7a9fa2cd1426021386,

title = "Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension",

abstract = "MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.",

keywords = "(±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate, CAS 86780-90-7, MPC-1304, antihypertensives, hypertension, essential",

author = "S. Suzuki and T. Hashimoto and S. Kusano and Kapuku, {Kakota Gaston} and T. Utsunomiya and K. Yano",

year = "1993",

month = jan,

day = "1",

language = "English (US)",

volume = "43",

pages = "1152--1156",

journal = "Drug Research",

issn = "2194-9379",

publisher = "Thieme",

number = "11",

}

TY - JOUR

T1 - Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension

AU - Suzuki, S.

AU - Hashimoto, T.

AU - Kusano, S.

AU - Kapuku, Kakota Gaston

AU - Utsunomiya, T.

AU - Yano, K.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.

AB - MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.

KW - (±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate

KW - CAS 86780-90-7

KW - MPC-1304

KW - antihypertensives

KW - hypertension, essential

UR - http://www.scopus.com/inward/record.url?scp=0027422072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027422072&partnerID=8YFLogxK

M3 - Article

C2 - 8292057

AN - SCOPUS:0027422072

VL - 43

SP - 1152

EP - 1156

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 11

ER -